EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of single‐nucleotide polymorphism microarray in the classification of BAP1 ‐inactivated melanocytic tumours

Joseph S Durgin iD, Nicholas A Zoumberos iD, Taylor Novice iD, Douglas R Fullen iD, Alexandra C Hristov iD, Lori Lowe iD, Rajiv M Patel iD, Paul W Harms iD, Aleodor A Andea iD, Scott C Bresler iD

Histopathology · 2025

DOI: 10.1111/his.15434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Joseph S Durgin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Tumor Suppressor Proteins, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

BAP1‐inactivated melanocytic tumours (BIMTs) occur sporadically and in association with a familial tumour predisposition syndrome involving germline mutations in the BRCA1‐associated protein‐1 ( BAP1 ) gene. Here we report the clinical features, histopathologic findings, and chromosomal copy number data of 19 BAP1‐inactivated melanocytomas (BIMs) and compare their features to those of five BAP1‐inactivated melanomas.

Methods

We retrospectively searched the Department of Pathology archives and EMERSE (Electronic Medical Record Search Engine) for BIMTs that had undergone single‐nucleotide polymorphism (SNP) microarray testing. Clinical history/follow‐up data, detailed histopathologic features, and SNP microarray results were recorded.

Results

Overall, four patients (4/13) with BIMs and available clinical history had features suspicious for a germline BAP1 aberration. In BIMs (19 cases), the BAP1‐inactivated component showed variable cytologic features, including epithelioid (predominant), rhabdoid, plasmacytoid, and nevoid morphologies. Sentinel lymph node biopsy was negative in all (6/6) patients in which this procedure was performed. No patient diagnosed with a BIM with available clinical follow‐up (18/19; mean 38 months) experienced an adverse event. While the histologic appearances of the five melanomas varied, one case resembled a BIM. The median mitotic count was 1/mm 2 (range 0–6 mm 2 ) in BIMs compared to 3/mm 2 (range 1–4/mm 2 ) in melanomas ( P = 0.04). The median number of copy number alterations (CNAs) was two (range 0–6) in indolent cases versus seven (range 6–10) in melanomas ( P = 0.0005). The most common molecular aberration after loss of 3p21 was heterozygous loss of the CDKN2A locus, which unlike homozygous loss has not been associated with melanoma.

Conclusion

While most BIMs appear to have a favourable prognosis, even those with multiple CNAs, they deserve careful integration of all clinical and pathologic findings. Although not fully diagnostic, a mitotic count of ≥3/mm 2 and ≥6 CNAs in the appropriate context is supportive of a diagnosis of BAP1‐inactivated melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin ThiolesteraseTumor Suppressor ProteinsMelanomaSkin NeoplasmsHumansFemaleMalePolymorphism, Single NucleotideMiddle AgedAdultRetrospective StudiesAgedYoung Adult

Stichwörter der Autor:innen

BAP1‐inactivated melanocytomachromosomal microarray analysismelanomasingle nucleotide polymorphism microarray

Substanzen

Ubiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Pathology, University of Arkansas, Little Rock, Arkansas, USA.
  • Department of Dermatology, University of Arkansas, Little Rock, Arkansas, USA.
  • Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Cutaneous Pathology, WCP Laboratories Inc., Maryland Heights, Missouri, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Joseph S Durgin, Nicholas A Zoumberos, Taylor Novice, Douglas R Fullen, Alexandra C Hristov, Lori Lowe, Rajiv M Patel, Paul W Harms, Aleodor A Andea, Scott C Bresler

Förderung

  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Durgin, J. S., Zoumberos, N. A., Novice, T., Fullen, D. R., Hristov, A. C., Lowe, L., Patel, R. M., Harms, P. W., Andea, A. A., & Bresler, S. C. (2025). Role of single‐nucleotide polymorphism microarray in the classification of BAP1 ‐inactivated melanocytic tumours. Histopathology. https://doi.org/10.1111/his.15434

Vancouver

Durgin JS, Zoumberos NA, Novice T, Fullen DR, Hristov AC, Lowe L, et al. Role of single‐nucleotide polymorphism microarray in the classification of BAP1 ‐inactivated melanocytic tumours. Histopathology. 2025. doi:10.1111/his.15434

BibTeX
@article{Durgin2025,
  author = {Durgin, Joseph S and Zoumberos, Nicholas A and Novice, Taylor and Fullen, Douglas R and Hristov, Alexandra C and Lowe, Lori and Patel, Rajiv M and Harms, Paul W and Andea, Aleodor A and Bresler, Scott C},
  title = {Role of single‐nucleotide polymorphism microarray in the classification of BAP1 ‐inactivated melanocytic tumours},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15434}
}
Kostenlos starten →